California Increases Antitrust Penalties
What You Need to Know
Key takeaway #1
California increased civil and criminal antitrust penalties.
Key takeaway #2
Uncertainty remains regarding whether courts will actually impose the increased penalties.
Key takeaway #3
The California AG’s Antitrust Division can now use recovered fines to fund enforcement activities.
Client Alert | 1 min read | 10.27.25
Earlier this month, California enacted Senate Bill 763 (“SB 763”). The legislation amends the state’s long-standing antitrust statute, the Cartwright Act, to increase both criminal and civil maximum penalties for corporations and individuals. California Attorney General Rob Bonta, whose office is responsible for enforcing the Cartwright Act and stands to benefit from any civil penalties recovered under the new law, sponsored the bill.
Under the new law, maximum corporate criminal fines for each violation will increase from $1 million to $6 million and individual maximum criminal fines will increase from $250,000 to $1 million per violation. In actions brought by the Attorney General or a district attorney, courts can impose civil penalties of up to $1 million per violation based on factors including nature, seriousness and persistence of the misconduct. The new law does not specify what constitutes a “violation” (e.g., whether it pertains to each anticompetitive agreement, or each sale at a supracompetitive price made pursuant to an anticompetitive agreement). The law also gives the courts discretion to apply fines or penalties under the maximum statutory amounts.
California Attorney General Bonta is an active enforcer of California’s antitrust laws and an avid supporter of the bill. The bill also provides that any damages or criminal fines recovered by the Attorney General will be deposited in the Attorney General’s antitrust account rather than the state’s general fund, as before. This added source of funds may provide the Attorney General with additional resources and incentives to pursue antitrust enforcement.
Crowell & Moring’s team is closely monitoring these developments and is prepared to help your business navigate antitrust compliance and risk-mitigation strategies.
Contacts
Insights
Client Alert | 3 min read | 01.21.26
Atlantic Biologicals Opioid DPA: DOJ Continues Ramp Up of Criminal Corporate Healthcare Enforcement
On January 13, 2026, Miami-based pharmaceutical wholesaler Atlantic Biologicals Corporation entered into a two-year DPA, admitting to conspiracy to distribute and dispense controlled substances, including more than 14 million opioid doses to “pill mill” pharmacies in Texas at a markup. The DOJ and DEA underscored the company’s deliberate evasion of compliance checks and disregard for red flags signaling diversion.
Client Alert | 3 min read | 01.21.26
FedRAMP Proposes Updates to Authorization Process—Six New RFCs Released for Public Comment
Client Alert | 3 min read | 01.20.26
DoW Joins SBA’s Fight Against Alleged Pass-Through Fraud in the 8(a) Program
Client Alert | 3 min read | 01.20.26
Federal Government Challenges Minnesota Law Requiring Affirmative Action in State Government



